Pharmacokinetics and pharmacodynamics of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in renal transplantation: a comparison between Japanese and non-Japanese patients.
Haba
T
T
Department of Transplant Surgery, Nagoya Daini Red Cross Hospital, Japan.
Uchida
K
K
Katayama
A
A
Tominaga
Y
Y
Sato
T
T
Watanabe
I
I
Inagaki
H
H
Kimata
T
T
Goto
K
K
Morozumi
K
K
Takeda
A
A
Takahara
S
S
Takahashi
K
K
Oshima
S
S
D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology; D000077552:Basiliximab; D005006:Ethnicity; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D007564:Japan; D016030:Kidney Transplantation / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000187:drug effects / Q000276:immunology; D011993:Recombinant Fusion Proteins; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013997:Time Factors
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab